CJC-1295 (DAC)

Scientific Overview

CJC-1295 is a long-acting growth hormone–releasing hormone (GHRH) analog designed for prolonged GH and IGF-1 elevation via albumin binding (DAC versions).

Mechanism focus

Stimulates pituitary GHRH receptors; DAC chemistry extends half-life, producing multi-day GH/IGF-1 elevation in human pharmacokinetic studies.

Research Use Cases

• Long-acting GHRH pharmacology
• GH/IGF-1 axis kinetics
• Serum proteome response to sustained GH drive
• Anti-doping detection of GHRH analogs

Use-Case Study Notations

• Case-study notation: clinical pharmacology papers showed prolonged GH and IGF-1 secretion after CJC-1295.
• Case-study notation: once-daily dosing studies quantified enhanced GH/IGF-1 profiles versus shorter GHRH fragments.
• Specify DAC vs non-DAC material in documentation—half-life differs substantially.

Selected Studies

1. 01 Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting GH releasing hormone analogPubMed 16352683
2. 02 Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, enhances GH and IGF-I secretionPubMed 16822960
3. 03 Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changesPubMed 19386527
4. 04 Advances in the detection of growth hormone releasing hormone synthetic analogsPubMed 34665524
5. 05 Probing for peptidic drugs (2–10 kDa) in doping control blood samplesPubMed 38716080

Related compounds

Ipamorelin · Tesamorelin